Shattuck Labs, Inc. Common Stock (STTK) is a publicly traded Healthcare sector company. As of May 20, 2026, STTK trades at $6.29 with a market cap of $457.78M and a P/E ratio of -10.20. STTK moved +6.82% today. Year to date, STTK is +58.61%; over the trailing twelve months it is +499.03%. Its 52-week range spans $0.69 to $8.33. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces STTK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Shattuck Labs Completes Phase 1 Enrollment, Q1 Cash Grows to $90.4 Million: Shattuck Labs closed Q1 2026 with $90.4 million in cash and equivalents, up from $60.9 million a year earlier, funding operations into 2029. SL-325 Phase 1 enrollment is complete with data expected in Q2, Phase 2 Crohn’s trial slated for Q3, and its lead bispecific antibody enters IND-enabling activities.
| Metric | Value |
|---|---|
| Price | $6.29 |
| Market Cap | $457.78M |
| P/E Ratio | -10.20 |
| EPS | $-0.59 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.33 |
| 52-Week Low | $0.69 |
| Volume | 279.60K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.00M |
| Net Income | $-49.87M |
| Gross Margin | 0.00% |
7 analysts cover STTK: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.